Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

40.24 -0.79 (-1.93%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 867,418
Open 41.27
Bid (Size) 40.22 (100)
Ask (Size) 40.26 (100)
Prev. Close 41.03
Today's Range 39.91 - 41.88
52wk Range 14.14 - 42.81
Shares Outstanding 128,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? ↗
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill

Performance

YTD
+12.6%
+12.6%
1 Month
+15.4%
+15.4%
3 Month
+32.0%
+32.0%
6 Month
+12.6%
+12.6%
1 Year
+173.0%
+173.0%

More News

Read More
News headline image
What to Know About This Fund's $74.8 Million Indivior Sale ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗
Via The Motley Fool
Topics Regulatory Compliance
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗
Via Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗
Via Chartmill
News headline image
What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗
Via Chartmill
News headline image
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior Announces $175 Million Accelerated Share Repurchase
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior (INDV) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Announces Proposed Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Divisadero Dumps Stride Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior (INDV) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Indivior Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Indivior Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Indivior Pharmaceuticals, Inc. - Common Stock trade on?
Indivior Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock is INDV on the Nasdaq Stock Market
What is the current price of Indivior Pharmaceuticals, Inc. - Common Stock?
The current price of Indivior Pharmaceuticals, Inc. - Common Stock is 40.24
When was Indivior Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Indivior Pharmaceuticals, Inc. - Common Stock was at 07/01/26 03:29 PM ET
What is the market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock is 5.15B
How many shares of Indivior Pharmaceuticals, Inc. - Common Stock are outstanding?
Indivior Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.